Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
Takeda Pharmaceutical enjoyed an 8.5-fold leap in net profit in the year through March 2021 as it yielded gains on a series of non-core asset divestitures and booked lower expenses related to the Shire acquisition made in January 2019, the…
To read the full story
Related Article
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
February 5, 2021
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
BUSINESS
- Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
- FDA Places Clinical Hold on MPS Gene Therapies: Regenxbio/Nippon Shinyaku
January 30, 2026
- Astellas Positions Izervay as Key Entry Drug in Ophthalmology Push
January 30, 2026
- Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
- Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…